BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
https://doi.org/10.17749/2070-4909.2015.8.1.039-046
Abstract
We have performed the first-ever Budget Impact Analysis (BIA) in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autological transplantation of stem cells isn’t shown. Research was conducted from a position of the state health system of the Russian Federation. Within the BIA the analysis of economic efficiency and availability of technology was carried also out to be allowing to estimate expediency of introduction of technology in the presence of the budgetary restrictions. It was as a result shown that use of bendamustine in comparing with strategy of a bortezomib is more preferable strategy from the point of view of BIA: application of a bendamustine allows to keep considerable budget funds – to 159 153 118 rub, thus the saved means allow to treat with this strategy in addition 29 patients during 25 month. It was defined that application of strategy of a bendamustin in comparison with the bortezomib involves smaller load of the budget, thus growth of efficiency is observed for indicator “time to disease progression”.
About the Authors
A. S. Kolbin
First St. Petersburg State Medical University named after Academician Pavlov;
Saint-Petersburg State Pediatric Medical University
Russian Federation
Kolbin Aleksei Sergeevich – MD, professor, head of department of clinical pharmacology and evidence-based medicine, First St. Petersburg State Medical University. Address: 197022, St. Petersburg, Leo Tolstoy, 6-8; Professor of the Department of Farmakology of St. Petersburg State University. Address: 21-Line, 8, St. Petersburg, VO, 199106, Russia. Tel.: +79217590449. E-mail: аlex.kolbin@mail.ru.
Russian Federation
Kolbin Aleksei Sergeevich – MD, professor, head of department of clinical pharmacology and evidence-based medicine, First St. Petersburg State Medical University. Address: 197022, St. Petersburg, Leo Tolstoy, 6-8; Professor of the Department of Farmakology of St. Petersburg State University. Address: 21-Line, 8, St. Petersburg, VO, 199106, Russia. Tel.: +79217590449. E-mail: аlex.kolbin@mail.ru.
I. A. Vilyum
First St. Petersburg State Medical University named after Academician Pavlov;
National Medical and Surgical Center named after NI Pirogov, St. Petersburg clinical complex
Russian Federation
Russian Federation
Vilyum Irina Aleksandrovna – assistant of professor, Department of clinical pharmacology and evidence-based medicine, FirstSt. PetersburgStateMedicalUniversity. Address: Lev Tolstoy 6-8, St. Petersburg, 197022, Russia. E-mail: i-velum@yandex.ru.
M. A. Proskurin
Saint-Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Proskurin Maksim Alexandrovich – researcher, Saint-PetersburgStateUniversity, Saint-Petersburg. Address: Universitetskii pr., St. Petersburg35, 198504, Russia. Tel.: +79119003340. E-mail: proskurin.m@gmail.com.
Yu. E. Balykina
Saint-Petersburg State Pediatric Medical University
Russian Federation
Balykina Yulia Efimovna – PhD, senior lecturer, Saint-Petersburg State University, Saint-Petersburg. Address:Universitetskii pr., St. Petersburg 35, 198504, Russia. Tel.: +79117378634. E-mail: julia.balykina@gmail.com
Russian Federation
Balykina Yulia Efimovna – PhD, senior lecturer, Saint-Petersburg State University, Saint-Petersburg. Address:Universitetskii pr., St. Petersburg 35, 198504, Russia. Tel.: +79117378634. E-mail: julia.balykina@gmail.com
References
1. Abdulkadyrov K.M. Clinical hematology [Klinicheskaya gematologiya]. St. Petersburg. 2006; 447 s.
2. Andreeva N.E. Paroproteinemicheskie gemablostozy: Multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease / NE Andreeva, TV Balakirev [Paroproteinemicheskie gemablostozy: Mnozhestvennaya mielo-ma, makroglobulinemiya Val'denstrema, bolezni tyazhelykh tsepei / N.E. Andreeva, T.V. Balakireva]. Tver'. 2003; 88 s.
3. Kolbin A.S., Vilyum I.A., Proskurin M.A., Balykina Yu.E. FARMAKOEKONOMIKA. Sovremenennaya farmakoekonomika i Farmakoepidemiologiya. 2014; 7 (2): 6-12.
4. National clinical guidelines for diagnosis and treatment of multiple myeloma [Natsional'nye klinicheskie rekomendatsii po diagnostike i lecheniyu mnozhe-stvennoi mielomy]. Gematologiya i transfuziologiya. Prilozhenie № 3. 2014; 1.
5. On approval of the industry-standard «clinical and research ekonomieskie. General Provisions»: the order №163 of the Ministry of Health of the Russian Federation dated 27.05.2011. [Ob utverzhdenii otraslevogo standarta «kliniko-ekonomieskie issledovaniya. Obshchie polozheniya»: prikaz №163 Ministerstva Zdravookhraneniya Rossiiskoi Federatsii ot 27.05.2011].
6. Government Decree of October 22, 2012 № 1074 «About the state guarantees the free provision of medical care to citizens in 2013 and the planned period 2014 and 2015» [Postanovlenie Pravitel'stva RF ot 22 oktyabrya 2012 g. № 1074 «O programme gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi na 2013 god i na planovyi period 2014 i 2015 godov»].
7. Available to the Committee on Economic Policy and Strategic planing of St. Petersburg from 17.07.2013 N 103-r «On approval of the fi nancial-the cost of providing public services (works) for spe-wamedical care in geriatric institutions (otde -leniyah, offices), care provided in hospices (offices, hospices), and medical care provided in nursing departments, autonomous government and the public institutions» [Rasporyazhenie Komiteta po ekonomicheskoi politike istrategicheskomu pla-nirovaniyu Sankt-Peterburga ot 17.07.2013 N 103-r «Ob utverzhdenii normativov fi-nansovykh zatrat na okazanie gosudarstvennykh uslug (vypolnenie rabot) po spetsiali-zirovannoi meditsinskoi pomoshchi, okazyvaemoi v geriatricheskikh uchrezhdeniyakh (otde-leniyakh, kabinetakh), meditsinskoi pomoshchi, okazyvaemoi v khospisakh (otdeleniyakh-khospisakh), i meditsinskoi pomoshchi, okazyvaemoi v otdeleniyakh sestrinskogo ukhoda, gosudarstvennymi avtonomnymi i byudzhetnymi uchrezhdeniyami»].
8. Site of the State register of medicines. http://grls.rosminzdrav.ru.
9. Cheson B.D., Rummel M.J. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009; 27: 1492-501.
10. Hong Anh T.Tu., Robin de Vries., Herman J. Woerdenbag. et al. Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Afford-ability Curves in Health Care Decision Making. Value in Health Regional. 2012; 1:7-14.
11. http://www.spboms.ru/kiop/main?page_id=338.
12. http://www.pokrov.spb.ru/stoimostq-uslug.html.
13. ISPOR TASK: Sullivan S., Mauskopf J., Augustovski F. et al. Budget Impact Analysis – Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in health. 2014; 17: 5-14.
14. Josephine A. Mauskopf et al. Principles of Good Practice for Budget Impact Analysis: Re-port of the ISPOR Task Force on Good Research Practices – Budget Impact Analysis. Value in Health. 2007; 10 (5): 336-347.
15. Leoni L et al. Clin Cancer Res. 2008; 309 (14): 309-317.
16. Ponisch W. et al. Treatment of bendamustine and prednisone in patients with newly diag-nosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006; 132 (4): 205-12.
17. Rummel M.J., Al-Batran S., Kim S.Z. et al. Ribomustin plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle-cell and low-grade non-Hodgkin's lym-phoma. J Clin Oncol. 2005; 23: 3383-3389.
18. Sendi P.P., Briggs A.H. Affordability and cost-effectiveness: decision making on the cost-effectiveness plane. Health Econ. 2001; 10: 675-80.
19. www.medlux.ru.
Review
For citations:
Kolbin A.S., Vilyum I.A., Proskurin M.A., Balykina Yu.E. BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2015;8(1):39-46. (In Russ.) https://doi.org/10.17749/2070-4909.2015.8.1.039-046
Views:
1436
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 